

ForPatients

by Roche

COVID-19 Pneumonia

## A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia

**Trial Status**  
Completed

**Trial Runs In**  
4 Countries

**Trial Identifier**  
NCT04409262 2020-002275-34  
WA42511

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

### ***Trial Summary:***

This study will evaluate the efficacy and safety of combination therapy with remdesivir plus tocilizumab compared with remdesivir plus placebo in hospitalized patients with COVID-19 pneumonia.

**Hoffmann-La Roche**  
Sponsor

**Phase 3**  
Phase

---

**NCT04409262 2020-002275-34 WA42511**  
Trial Identifiers

---

### ***Eligibility Criteria:***

**Gender**  
All

**Age**  
>=12 Years

**Healthy Volunteers**  
No

---